Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.
- M. Shiffman, F. Suter, +8 authors S. Zeuzem
- Medicine
- The New England journal of medicine
- 12 July 2007
BACKGROUND
Patients infected with hepatitis C virus (HCV) genotype 2 or 3 have sustained virologic response rates of approximately 80% after receiving treatment with peginterferon and ribavirin for… Expand
Analysis of ISG expression in chronic hepatitis C identifies viperin as a potential antiviral effector
- K. Helbig, D. T. Lau, L. Semendric, H. Harley, M. R. Beard
- Biology, Medicine
- Hepatology
- 1 September 2005
Interferon (IFN) α inhibits hepatitis C virus (HCV) replication both clinically and in vitro; however, the complete spectrum of interferon‐stimulated genes (ISGs) expressed in the HCV‐infected liver… Expand
Transferrin index: an alternative method for calculating the iron saturation of transferrin.
- J. Beilby, J. Olynyk, +5 authors P. Garcia-Webb
- Chemistry, Medicine
- Clinical chemistry
- 1 October 1992
We surveyed 140 clinical chemistry laboratories in Australia to establish which laboratory methods they used to determine serum iron status: 125 measured serum iron (Fe), 85 measured transferrin… Expand
Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.
- Gregory J. Dore, E. Lawitz, +24 authors E. Hughes
- Medicine
- Gastroenterology
- 1 February 2015
BACKGROUND & AIMS
Twenty-four weeks of treatment with peginterferon and ribavirin for chronic hepatitis C virus (HCV) genotype 2 or 3 infection produces a sustained virologic response (SVR) in… Expand
Donor mannose-binding lectin deficiency increases the likelihood of clinically significant infection after liver transplantation.
- D. Worthley, D. Johnson, +9 authors C. Mullighan
- Medicine
- Clinical infectious diseases : an official…
- 15 February 2009
BACKGROUND
Mannose-binding lectin (MBL) is an important mediator of innate immunity and is synthesized primarily by the liver. Low MBL levels are common, are due primarily to polymorphisms in the… Expand
Differential Expression of the CXCR3 Ligands in Chronic Hepatitis C Virus (HCV) Infection and Their Modulation by HCV In Vitro
- K. Helbig, A. Ruszkiewicz, +4 authors M. R. Beard
- Biology, Medicine
- Journal of Virology
- 5 November 2008
ABSTRACT To investigate chemokine expression networks in chronic hepatitis C virus (HCV) infection, we used microarray analysis to determine chemokine expression in human infection and in chimpanzees… Expand
Expression of the CXCR3 ligand I‐TAC by hepatocytes in chronic hepatitis C and its correlation with hepatic inflammation
- K. Helbig, A. Ruszkiewicz, L. Semendric, H. Harley, S. McColl, M. R. Beard
- Biology, Medicine
- Hepatology
- 1 May 2004
The factors that regulate lymphocyte traffic in chronic hepatitis C (CHC) are not completely defined. Interferon (IFN)‐inducible T cell α chemoattractant (I‐TAC) is a relatively new member of the… Expand
Combination low‐dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B
- P. Angus, G. McCaughan, E. Gane, D. Crawford, H. Harley
- Medicine
- Liver transplantation : official publication of…
- 1 July 2000
Although antiviral prophylaxis with lamivudine monotherapy appears to reduce post–liver transplantation recurrence of hepatitis B virus (HBV) infection, breakthrough infections occur in at least 20%… Expand
High prevalence of late relapse and reinfection in prisoners treated for chronic hepatitis C
- J. Bate, Anton Colman, P. Frost, D. Shaw, H. Harley
- Medicine
- Journal of gastroenterology and hepatology
- 1 July 2010
Background and Aim: Prisoners have a high prevalence of injection drug use (IDU) and chronic hepatitis C (CHC) infection. Treatment of CHC in these patients is effective; however, their long‐term… Expand
Factors associated with severity of hepatic fibrosis in people with chronic hepatitis C infection
- M. Danta, Gregory J. Dore, +10 authors Geoff C Farrell
- Medicine
- The Medical journal of Australia
- 1 September 2002
Objective: To determine factors associated with hepatic fibrosis development in people with chronic hepatitis C virus (HCV) infection.